This technology concerns a method for measuring the concentration of fibrinogen protein in human blood samples and nanoparticles for this purpose.
Conventional fibrinogen measurement methods had significant limitations, such as large errors and long processing times, stemming from enzyme activity effects and the need for reference plasma measurements.
This technology is convenient as it does not use enzymes, eliminates errors caused by enzyme activity factors, and reduces measurement time by eliminating the need for reference measurements. Consequently, it offers superior accuracy, precision, and reproducibility compared to existing methods.
US2021-0116448A1